Is Evexia Lifecare overvalued or undervalued?

As of 3 October 2025, Evexia Lifecare's valuation grade has moved from expensive to very expensive, indicating a significant deterioration in its valuation outlook. The company is currently assessed as overvalued, with a PE ratio of 216.70, an EV to EBITDA ratio of 208.63, and a ROE of only 0.31%. These ratios starkly contrast with peers such as Castrol India, which has a PE ratio of 20.95, and Gulf Oil Lubricants, with a PE ratio of 16.35, highlighting the extreme valuation of Evexia Lifecare.
The company's financial metrics suggest a troubling investment scenario, especially given its negative stock performance, with a year-to-date return of -41.45% compared to a positive 3.93% return for the Sensex. This stark underperformance, combined with the high valuation ratios, reinforces the conclusion that Evexia Lifecare is not a favorable investment at this time.